ERBB2
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O43157 | Y1708 | EPSD|PSP | PLXNB1 KIAA0407 PLXN5 SEP | TNWMSICLYTFVRDSVGEPLyMLFRGIKHQVDKGPVDSVTG |
| O43157 | Y1732 | EPSD|PSP | PLXNB1 KIAA0407 PLXN5 SEP | RGIKHQVDKGPVDSVTGKAKyTLNDNRLLREDVEYRPLTLN |
| O75347 | Y75 | Sugiyama | TBCA | EILQEsRMMIPDCQRRLEAAyLDLQRILENEKDLEEAEEyK |
| P00338 | Y10 | EPSD|PSP | LDHA PIG19 | ___________MAtLKDQLIyNLLKEEQtPQNKITVVGVGA |
| P00338 | Y239 | Sugiyama | LDHA PIG19 | GtDKDKEQWKEVHKQVVEsAyEVIKLKGYtSWAIGLSVADL |
| P00533 | Y1069 | iPTMNet|EPSD | EGFR ERBB ERBB1 HER1 | CIDRNGLQsCPIKEDsFLQRyssDPtGALtEDsIDDtFLPV |
| P00558 | Y161 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | KAEPAKIEAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNL |
| P04626 | S1054 | Sugiyama | ERBB2 HER2 MLN19 NEU NGL | DPAPGAGGMVHHRHRssstRsGGGDLtLGLEPsEEEAPRsP |
| P04626 | S1100 | Sugiyama | ERBB2 HER2 MLN19 NEU NGL | GAGsDVFDGDLGMGAAKGLQsLPtHDPsPLQRySEDPTVPL |
| P04626 | S1107 | Sugiyama | ERBB2 HER2 MLN19 NEU NGL | DGDLGMGAAKGLQsLPtHDPsPLQRySEDPTVPLPSETDGY |
| P04626 | T1103 | Sugiyama | ERBB2 HER2 MLN19 NEU NGL | sDVFDGDLGMGAAKGLQsLPtHDPsPLQRySEDPTVPLPSE |
| P04626 | Y1023 | SIGNOR|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | tFyRSLLEDDDMGDLVDAEEyLVPQQGFFCPDPAPGAGGMV |
| P04626 | Y1112 | SIGNOR|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | MGAAKGLQsLPtHDPsPLQRySEDPTVPLPSETDGYVAPLT |
| P04626 | Y1139 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | PLPSETDGYVAPLTCSPQPEyVNQPDVRPQPPsPREGPLPA |
| P04626 | Y1196 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | GKNGVVKDVFAFGGAVENPEyLTPQGGAAPQPHPPPAFSPA |
| P04626 | Y1221 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | GGAAPQPHPPPAFSPAFDNLyyWDQDPPERGAPPstFKGtP |
| P04626 | Y1222 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | GAAPQPHPPPAFSPAFDNLyyWDQDPPERGAPPstFKGtPt |
| P04626 | Y1248 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ERBB2 HER2 MLN19 NEU NGL | PERGAPPstFKGtPtAENPEyLGLDVPV_____________ |
| P04626 | Y877 | EPSD|PSP|Sugiyama | ERBB2 HER2 MLN19 NEU NGL | NHVKITDFGLARLLDIDEtEyHADGGKVPIKWMALESILRR |
| P06493 | Y15 | SIGNOR|EPSD|PSP | CDK1 CDC2 CDC28A CDKN1 P34CDC2 | ______MEDyTKIEKIGEGtyGVVyKGRHKTTGQVVAMKKI |
| P06733 | Y44 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | LFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKGVSK |
| P07205 | Y161 | Sugiyama | PGK2 PGKB | KAEPDKIEAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNL |
| P07355 | Y188 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | RKLMVALAKGRRAEDGsVIDyELIDQDARDLyDAGVKRKGT |
| P07355 | Y199 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | RAEDGsVIDyELIDQDARDLyDAGVKRKGTDVPKWIsIMTE |
| P07814 | S883 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | QYKEKTGKEyIPGQPPLsQssDssPtRNsEPAGLEtPEAKV |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y484 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVR |
| P11142 | Y41 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P13667 | Y458 | Sugiyama | PDIA4 ERP70 ERP72 | VLEVAKDFPEytFAIADEEDyAGEVKDLGLsEsGEDVNAAI |
| P17066 | Y43 | Sugiyama | HSPA6 HSP70B' | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P25398 | Y127 | Sugiyama | RPS12 | sCVVVKDYGKESQAKDVIEEyFKCKK_______________ |
| P34931 | Y43 | Sugiyama | HSPA1L | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P35222 | Y654 | EPSD|PSP | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | EGATAPLTELLHsRNEGVAtyAAAVLFRMSEDKPQDyKKRL |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P42685 | S498 | Sugiyama | FRK PTK5 RAK | PTFETLRWKLEDyFETDssysDANNFIR_____________ |
| P42685 | Y490 | Sugiyama | FRK PTK5 RAK | WNAEPKERPTFETLRWKLEDyFETDssysDANNFIR_____ |
| P42685 | Y497 | Sugiyama | FRK PTK5 RAK | RPTFETLRWKLEDyFETDssysDANNFIR____________ |
| P48741 | Y43 | Sugiyama | HSPA7 HSP70B | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P51991 | Y360 | Sugiyama | HNRNPA3 HNRPA3 | QSNYGPMKGGsFGGRssGsPyGGGyGsGGGsGGyGsRRF__ |
| P54652 | Y42 | Sugiyama | HSPA2 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P60660 | Y89 | Sugiyama | MYL6 | HFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMGAEI |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P63220 | Y53 | Sugiyama | RPS21 | QMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRLA |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q01082 | S2165 | Sugiyama | SPTBN1 SPTB2 | VDTsEMVNGAtEQRtssKEssPIPsPtsDRKAKTALPAQsA |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q13615 | T618 | Sugiyama | MTMR3 KIAA0371 ZFYVE10 | TSPDDPPLSRLPKtRsyDNLttACDNTVPLASRRCsDPSLN |
| Q58FF8 | Y260 | Sugiyama | HSP90AB2P HSP90BB | VRYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVW |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q86TC9 | S928 | Sugiyama | MYPN MYOP | FEQRLMNEIEFRLERtPVDEsDDEIQHDEIPTGKCIAPIFD |
| Q86V81 | Y250 | Sugiyama | ALYREF ALY BEF THOC4 | AGRNSKQQLsAEELDAQLDAyNARMDts_____________ |
| Q86W56 | Y832 | Sugiyama | PARG | DDWQRRCTEIVAIDALHFRRyLDQFVPEKMRRELNKAYCGF |
| Q8NI22 | Y135 | Sugiyama | MCFD2 SDNSF | DELINIIDGVLRDDDKNNDGyIDyAEFAKSLQ_________ |
| Q92574 | S511 | Sugiyama | TSC1 KIAA0243 TSC | TAEAEPVVPRGGFDsPFyRDsLPGsQRKtHsAAsssQGASV |
| Q92574 | Y508 | Sugiyama | TSC1 KIAA0243 TSC | EITTAEAEPVVPRGGFDsPFyRDsLPGsQRKtHsAAsssQG |
| Q96N67 | Y1257 | SIGNOR|EPSD|PSP | DOCK7 KIAA1771 | RVAMLYLPLIGIIMETVPQLyDFTETHNQRGRPICIATDDY |
| Q9BQE3 | Y432 | Sugiyama | TUBA1C TUBA6 | GMEEGEFSEAREDMAALEKDyEEVGADsADGEDEGEEy___ |
| Q9BXH1 | Y152 | SIGNOR|EPSD|PSP | BBC3 PUMA | QWAREIGAQLRRMADDLNAQyERRRQEEQQRHRPSPWRVLy |
| Q9BXH1 | Y172 | SIGNOR|EPSD|PSP | BBC3 PUMA | yERRRQEEQQRHRPSPWRVLyNLIMGLLPLPRGHRAPEMEP |
| Q9BXH1 | Y58 | SIGNOR|EPSD|PSP | BBC3 PUMA | GLCEPGLAAAPAAPTLLPAAyLCAPTAPPAVTAALGGSRWP |
| Q9H1E3 | Y146 | Sugiyama | NUCKS1 NUCKS JC7 | QEKDsGsDEDFLMEDDDDsDyGSsKKKNKKMVKKSKPERKE |
| Q9HB20 | S248 | Sugiyama | PLEKHA3 FAPP1 | PVstLHRLsQRRRRtYsDtDsCsDIPLEDPDRPVHCSKNTL |
| Q9NWB6 | S76 | Sugiyama | ARGLU1 | sRsRstNTAVSRRERDRERAssPPDRIDIFGRTVSKRSSLD |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Packaging Of Telomere Ends | R-HSA-171306 | 1.583178e-13 | 12.800 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.583178e-13 | 12.800 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 5.706546e-14 | 13.244 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.968736e-13 | 12.527 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 9.815482e-13 | 12.008 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 7.133183e-13 | 12.147 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.404699e-13 | 12.027 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.600386e-12 | 11.796 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.600386e-12 | 11.796 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.652767e-12 | 11.576 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.384515e-12 | 11.471 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.384515e-12 | 11.471 | 0 | 0 |
| Depurination | R-HSA-73927 | 4.293566e-12 | 11.367 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 5.323297e-12 | 11.274 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 6.800005e-12 | 11.167 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 6.800005e-12 | 11.167 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.814194e-12 | 11.107 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 8.492873e-12 | 11.071 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.492873e-12 | 11.071 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.306222e-11 | 10.884 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.306222e-11 | 10.884 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.609124e-11 | 10.793 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.189482e-11 | 10.660 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.411560e-11 | 10.618 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.411560e-11 | 10.618 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 2.592659e-11 | 10.586 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.934719e-11 | 10.532 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.996747e-11 | 10.398 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 4.297829e-11 | 10.367 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 4.866507e-11 | 10.313 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 6.578615e-11 | 10.182 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 7.421141e-11 | 10.130 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 8.845757e-11 | 10.053 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.051168e-10 | 9.978 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.051168e-10 | 9.978 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.173059e-10 | 9.931 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.245448e-10 | 9.905 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.566626e-10 | 9.805 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.698448e-10 | 9.770 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.387218e-10 | 9.622 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.790647e-10 | 9.554 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 3.254268e-10 | 9.488 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.393628e-10 | 9.357 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.394205e-10 | 9.357 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 4.675520e-10 | 9.330 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 4.675520e-10 | 9.330 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 8.550068e-10 | 9.068 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 8.960727e-10 | 9.048 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.075624e-09 | 8.968 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.341625e-09 | 8.872 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.295901e-09 | 8.887 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.390230e-09 | 8.857 | 1 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.417712e-09 | 8.848 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.529193e-09 | 8.816 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.529193e-09 | 8.816 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.240984e-09 | 8.650 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.308632e-09 | 8.637 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.867522e-09 | 8.542 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 3.646416e-09 | 8.438 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 4.609368e-09 | 8.336 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 5.171262e-09 | 8.286 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 5.171262e-09 | 8.286 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 7.253852e-09 | 8.139 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 7.253852e-09 | 8.139 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 8.081977e-09 | 8.092 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.583862e-09 | 8.018 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.237639e-08 | 7.907 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.493951e-08 | 7.826 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 1.520696e-08 | 7.818 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.635710e-08 | 7.786 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 3.465450e-08 | 7.460 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 3.643312e-08 | 7.439 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 4.376295e-08 | 7.359 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.544351e-08 | 7.256 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.544351e-08 | 7.256 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.544351e-08 | 7.256 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 5.722401e-08 | 7.242 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 5.722401e-08 | 7.242 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 6.062311e-08 | 7.217 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 6.809520e-08 | 7.167 | 1 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 6.452264e-08 | 7.190 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.426295e-07 | 6.846 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.680697e-07 | 6.775 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.120410e-07 | 6.674 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.248367e-07 | 6.648 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.652113e-07 | 6.576 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 3.302813e-07 | 6.481 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 3.798332e-07 | 6.420 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.811492e-07 | 6.419 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.871684e-07 | 6.312 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 6.607629e-07 | 6.180 | 1 | 0 |
| Reproduction | R-HSA-1474165 | 7.060867e-07 | 6.151 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.262771e-07 | 6.139 | 1 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.677994e-07 | 6.014 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 9.993726e-07 | 6.000 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.143348e-06 | 5.942 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.693352e-06 | 5.771 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.273427e-06 | 5.643 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.181676e-06 | 5.661 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 2.451076e-06 | 5.611 | 1 | 1 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.539132e-06 | 5.595 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.016864e-06 | 5.520 | 1 | 1 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 3.187428e-06 | 5.497 | 0 | 0 |
| Immune System | R-HSA-168256 | 3.289701e-06 | 5.483 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 4.129622e-06 | 5.384 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 4.295942e-06 | 5.367 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 4.757411e-06 | 5.323 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 4.804610e-06 | 5.318 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.110323e-05 | 4.955 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.620668e-05 | 4.790 | 1 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.027636e-05 | 4.693 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.873063e-05 | 4.727 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.098813e-05 | 4.678 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.377802e-05 | 4.624 | 1 | 0 |
| HCMV Late Events | R-HSA-9610379 | 2.458429e-05 | 4.609 | 0 | 0 |
| M Phase | R-HSA-68886 | 3.739204e-05 | 4.427 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 4.396354e-05 | 4.357 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.476032e-05 | 4.349 | 1 | 1 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 4.621228e-05 | 4.335 | 1 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.923987e-05 | 4.308 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.795432e-05 | 4.237 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.390634e-05 | 4.027 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 9.928982e-05 | 4.003 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 1.265109e-04 | 3.898 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.546738e-04 | 3.811 | 1 | 1 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.764822e-04 | 3.753 | 1 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 1.908742e-04 | 3.719 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.013783e-04 | 3.696 | 1 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.363049e-04 | 3.627 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.607912e-04 | 3.584 | 1 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.808622e-04 | 3.552 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.952535e-04 | 3.403 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 5.610937e-04 | 3.251 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 6.135798e-04 | 3.212 | 0 | 0 |
| Disease | R-HSA-1643685 | 8.490798e-04 | 3.071 | 1 | 0 |
| Signaling by VEGF | R-HSA-194138 | 9.017428e-04 | 3.045 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 9.026565e-04 | 3.044 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.044920e-03 | 2.981 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.400431e-03 | 2.854 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.490989e-03 | 2.827 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.805281e-03 | 2.743 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.947627e-03 | 2.710 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.002379e-03 | 2.698 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.088544e-03 | 2.680 | 1 | 0 |
| IRS activation | R-HSA-74713 | 2.706227e-03 | 2.568 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.255275e-03 | 2.647 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.517053e-03 | 2.599 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.505355e-03 | 2.601 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.029601e-03 | 2.519 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.285283e-03 | 2.483 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 3.285283e-03 | 2.483 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 3.509743e-03 | 2.455 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.775047e-03 | 2.423 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 3.915706e-03 | 2.407 | 1 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 4.007318e-03 | 2.397 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 4.410727e-03 | 2.355 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 4.410727e-03 | 2.355 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 4.635394e-03 | 2.334 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.818705e-03 | 2.317 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.818705e-03 | 2.317 | 1 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.292620e-03 | 2.276 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 5.407015e-03 | 2.267 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 6.315960e-03 | 2.200 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 6.496479e-03 | 2.187 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 6.496479e-03 | 2.187 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 6.496479e-03 | 2.187 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 6.496479e-03 | 2.187 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 6.496479e-03 | 2.187 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.721122e-03 | 2.173 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.721122e-03 | 2.173 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 6.988165e-03 | 2.156 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 8.946591e-03 | 2.048 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.677025e-03 | 2.115 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 8.946591e-03 | 2.048 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 8.470850e-03 | 2.072 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.082513e-03 | 2.092 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 8.946591e-03 | 2.048 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 8.946591e-03 | 2.048 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 7.752650e-03 | 2.111 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 8.402364e-03 | 2.076 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 9.791446e-03 | 2.009 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.030315e-02 | 1.987 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.030315e-02 | 1.987 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.033953e-02 | 1.985 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.074760e-02 | 1.969 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.074760e-02 | 1.969 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.074760e-02 | 1.969 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.074760e-02 | 1.969 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.074760e-02 | 1.969 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.074760e-02 | 1.969 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.074760e-02 | 1.969 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.074760e-02 | 1.969 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.074760e-02 | 1.969 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.074760e-02 | 1.969 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.074760e-02 | 1.969 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.074760e-02 | 1.969 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.074760e-02 | 1.969 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.074760e-02 | 1.969 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.074760e-02 | 1.969 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.074760e-02 | 1.969 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.074760e-02 | 1.969 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.074760e-02 | 1.969 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.074760e-02 | 1.969 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.074760e-02 | 1.969 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.074760e-02 | 1.969 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.074760e-02 | 1.969 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.074760e-02 | 1.969 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.074760e-02 | 1.969 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.074760e-02 | 1.969 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.074760e-02 | 1.969 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.074760e-02 | 1.969 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.074760e-02 | 1.969 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.074760e-02 | 1.969 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.074760e-02 | 1.969 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.074760e-02 | 1.969 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.170884e-02 | 1.931 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.174471e-02 | 1.930 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.655991e-02 | 1.781 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.326930e-02 | 1.877 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.655991e-02 | 1.781 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.566520e-02 | 1.805 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.396894e-02 | 1.855 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.762470e-02 | 1.754 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.787682e-02 | 1.748 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.832216e-02 | 1.737 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.832216e-02 | 1.737 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.835722e-02 | 1.736 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.928502e-02 | 1.715 | 1 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.015992e-02 | 1.696 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.015992e-02 | 1.696 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.023053e-02 | 1.694 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.071401e-02 | 1.684 | 1 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.129015e-02 | 1.672 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.138035e-02 | 1.670 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 2.207137e-02 | 1.656 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.207137e-02 | 1.656 | 1 | 1 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.232147e-02 | 1.651 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.446469e-02 | 1.611 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 2.610827e-02 | 1.583 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.797216e-02 | 1.553 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.823027e-02 | 1.549 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.867771e-02 | 1.542 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.867771e-02 | 1.542 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.867771e-02 | 1.542 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.935464e-02 | 1.532 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.041902e-02 | 1.517 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.046795e-02 | 1.516 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.159278e-02 | 1.500 | 1 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.189947e-02 | 1.496 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.189947e-02 | 1.496 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.189947e-02 | 1.496 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.189947e-02 | 1.496 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 3.410766e-02 | 1.467 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 3.451890e-02 | 1.462 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.499019e-02 | 1.456 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.736936e-02 | 1.427 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.736936e-02 | 1.427 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.736936e-02 | 1.427 | 1 | 1 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.980882e-02 | 1.400 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 4.230615e-02 | 1.374 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 4.230615e-02 | 1.374 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 4.230615e-02 | 1.374 | 0 | 0 |
| NTF3 activates NTRK3 signaling | R-HSA-9034013 | 4.230615e-02 | 1.374 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.260161e-02 | 1.279 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.260161e-02 | 1.279 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.260161e-02 | 1.279 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.260161e-02 | 1.279 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.260161e-02 | 1.279 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 4.747341e-02 | 1.324 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.013869e-02 | 1.300 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.230699e-02 | 1.374 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.747341e-02 | 1.324 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 6.131326e-02 | 1.212 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.844540e-02 | 1.233 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 5.231594e-02 | 1.281 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.392953e-02 | 1.357 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.260161e-02 | 1.279 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.562610e-02 | 1.255 | 1 | 1 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.230699e-02 | 1.374 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 5.956081e-02 | 1.225 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.167954e-02 | 1.380 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 4.428617e-02 | 1.354 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.107348e-02 | 1.386 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.244871e-02 | 1.372 | 1 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.244871e-02 | 1.372 | 1 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.107348e-02 | 1.386 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.835675e-02 | 1.316 | 1 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.244871e-02 | 1.372 | 1 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.500249e-02 | 1.260 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.747341e-02 | 1.324 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 4.932213e-02 | 1.307 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 6.278702e-02 | 1.202 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 6.278702e-02 | 1.202 | 1 | 1 |
| Regulation of gap junction activity | R-HSA-191650 | 6.278702e-02 | 1.202 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 6.278702e-02 | 1.202 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 6.278702e-02 | 1.202 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 6.278702e-02 | 1.202 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.364799e-02 | 1.196 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.718923e-02 | 1.173 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.727200e-02 | 1.172 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 7.286355e-02 | 1.137 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 7.286355e-02 | 1.137 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 7.286355e-02 | 1.137 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.286355e-02 | 1.137 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 7.286355e-02 | 1.137 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 7.286355e-02 | 1.137 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 7.324345e-02 | 1.135 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 7.633420e-02 | 1.117 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 7.633420e-02 | 1.117 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.633420e-02 | 1.117 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 7.946571e-02 | 1.100 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.263677e-02 | 1.083 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 8.263677e-02 | 1.083 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 8.283235e-02 | 1.082 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 8.283235e-02 | 1.082 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.283235e-02 | 1.082 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 8.283235e-02 | 1.082 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 8.283235e-02 | 1.082 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 8.283235e-02 | 1.082 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 8.283235e-02 | 1.082 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 8.283235e-02 | 1.082 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 8.283235e-02 | 1.082 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.283235e-02 | 1.082 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 8.283235e-02 | 1.082 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 8.584616e-02 | 1.066 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 8.674271e-02 | 1.062 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.694847e-02 | 1.061 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 8.909271e-02 | 1.050 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.237526e-02 | 1.034 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 9.269458e-02 | 1.033 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 9.269458e-02 | 1.033 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 1.024514e-01 | 0.989 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 1.024514e-01 | 0.989 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.024514e-01 | 0.989 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.024514e-01 | 0.989 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.024514e-01 | 0.989 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.024514e-01 | 0.989 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.121038e-01 | 0.950 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 1.121038e-01 | 0.950 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.121038e-01 | 0.950 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.121038e-01 | 0.950 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.216531e-01 | 0.915 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.216531e-01 | 0.915 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.311002e-01 | 0.882 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.311002e-01 | 0.882 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.404463e-01 | 0.852 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.404463e-01 | 0.852 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.496924e-01 | 0.825 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.588397e-01 | 0.799 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.588397e-01 | 0.799 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.588397e-01 | 0.799 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.588397e-01 | 0.799 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 1.678891e-01 | 0.775 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.678891e-01 | 0.775 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.768417e-01 | 0.752 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.768417e-01 | 0.752 | 1 | 1 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.856985e-01 | 0.731 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.856985e-01 | 0.731 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.856985e-01 | 0.731 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.856985e-01 | 0.731 | 1 | 1 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 9.904385e-02 | 1.004 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.162681e-01 | 0.935 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.162681e-01 | 0.935 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.415093e-01 | 0.849 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 1.024514e-01 | 0.989 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.496924e-01 | 0.825 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.162681e-01 | 0.935 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.162681e-01 | 0.935 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 9.904385e-02 | 1.004 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.311002e-01 | 0.882 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.162681e-01 | 0.935 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 1.121038e-01 | 0.950 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 1.754321e-01 | 0.756 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.754321e-01 | 0.756 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.678891e-01 | 0.775 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.678891e-01 | 0.775 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.678891e-01 | 0.775 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 1.024514e-01 | 0.989 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.588397e-01 | 0.799 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.944085e-02 | 1.002 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 1.121038e-01 | 0.950 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 1.092890e-01 | 0.961 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 1.311002e-01 | 0.882 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 1.311002e-01 | 0.882 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.588397e-01 | 0.799 | 1 | 1 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.588397e-01 | 0.799 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.856985e-01 | 0.731 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.452061e-01 | 0.838 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 1.564132e-01 | 0.806 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 1.016266e-01 | 0.993 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.244965e-01 | 0.905 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 1.644400e-01 | 0.784 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 1.564132e-01 | 0.806 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.803014e-01 | 0.744 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.216531e-01 | 0.915 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 1.311002e-01 | 0.882 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.768417e-01 | 0.752 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.245613e-01 | 0.905 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.678891e-01 | 0.775 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.415093e-01 | 0.849 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.127643e-01 | 0.948 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.092890e-01 | 0.961 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 1.515641e-01 | 0.819 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.216531e-01 | 0.915 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 1.588397e-01 | 0.799 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.292782e-01 | 0.888 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 9.904385e-02 | 1.004 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.092890e-01 | 0.961 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 1.768417e-01 | 0.752 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 1.566749e-01 | 0.805 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.311002e-01 | 0.882 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.588397e-01 | 0.799 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.216531e-01 | 0.915 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.263228e-01 | 0.899 | 1 | 0 |
| Kinesins | R-HSA-983189 | 1.677782e-01 | 0.775 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.404463e-01 | 0.852 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 1.404463e-01 | 0.852 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.588397e-01 | 0.799 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.588397e-01 | 0.799 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.588397e-01 | 0.799 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.856985e-01 | 0.731 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.105586e-01 | 0.956 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 1.305481e-01 | 0.884 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.588397e-01 | 0.799 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.856791e-01 | 0.731 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 1.768417e-01 | 0.752 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.526588e-01 | 0.816 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.785124e-02 | 1.009 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 1.316934e-01 | 0.880 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.588397e-01 | 0.799 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.856985e-01 | 0.731 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.856985e-01 | 0.731 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 1.136940e-01 | 0.944 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.749676e-01 | 0.757 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 1.305481e-01 | 0.884 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 1.404463e-01 | 0.852 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.092890e-01 | 0.961 | 1 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.174493e-01 | 0.930 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 9.512788e-02 | 1.022 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.233571e-01 | 0.909 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.320429e-01 | 0.879 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.172679e-01 | 0.931 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.870136e-01 | 0.728 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.870136e-01 | 0.728 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.870136e-01 | 0.728 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.883839e-01 | 0.725 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.944606e-01 | 0.711 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 1.944606e-01 | 0.711 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.944606e-01 | 0.711 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 1.944606e-01 | 0.711 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 1.944606e-01 | 0.711 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.944606e-01 | 0.711 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 1.944606e-01 | 0.711 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 1.944606e-01 | 0.711 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 1.947934e-01 | 0.710 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.000174e-01 | 0.699 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.026139e-01 | 0.693 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 2.031289e-01 | 0.692 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.031289e-01 | 0.692 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 2.031289e-01 | 0.692 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 2.085973e-01 | 0.681 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.104696e-01 | 0.677 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.104696e-01 | 0.677 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.117045e-01 | 0.674 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 2.117045e-01 | 0.674 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.117045e-01 | 0.674 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.117045e-01 | 0.674 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 2.117045e-01 | 0.674 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.117045e-01 | 0.674 | 1 | 1 |
| Signaling by Hippo | R-HSA-2028269 | 2.117045e-01 | 0.674 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.144092e-01 | 0.669 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.159546e-01 | 0.666 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.183557e-01 | 0.661 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.183557e-01 | 0.661 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.201883e-01 | 0.657 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 2.201883e-01 | 0.657 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 2.201883e-01 | 0.657 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.201883e-01 | 0.657 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.201883e-01 | 0.657 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.201883e-01 | 0.657 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 2.201883e-01 | 0.657 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.246958e-01 | 0.648 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.262673e-01 | 0.645 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.262673e-01 | 0.645 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.269785e-01 | 0.644 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 2.275020e-01 | 0.643 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 2.275020e-01 | 0.643 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 2.285813e-01 | 0.641 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.285813e-01 | 0.641 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.285813e-01 | 0.641 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.285813e-01 | 0.641 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 2.300486e-01 | 0.638 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.368845e-01 | 0.625 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 2.368845e-01 | 0.625 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.368845e-01 | 0.625 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.368845e-01 | 0.625 | 1 | 1 |
| PCP/CE pathway | R-HSA-4086400 | 2.381722e-01 | 0.623 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.381722e-01 | 0.623 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.450989e-01 | 0.611 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.450989e-01 | 0.611 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 2.450989e-01 | 0.611 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.450989e-01 | 0.611 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.461274e-01 | 0.609 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.461274e-01 | 0.609 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.500541e-01 | 0.602 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.532253e-01 | 0.596 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.532253e-01 | 0.596 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.532253e-01 | 0.596 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.532253e-01 | 0.596 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 2.612647e-01 | 0.583 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.612647e-01 | 0.583 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 2.612647e-01 | 0.583 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 2.612647e-01 | 0.583 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.612647e-01 | 0.583 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 2.612647e-01 | 0.583 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.660501e-01 | 0.575 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 2.692181e-01 | 0.570 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 2.692181e-01 | 0.570 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.692181e-01 | 0.570 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.692181e-01 | 0.570 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.692181e-01 | 0.570 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 2.692181e-01 | 0.570 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 2.703101e-01 | 0.568 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 2.728919e-01 | 0.564 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 2.770864e-01 | 0.557 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.770864e-01 | 0.557 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.770864e-01 | 0.557 | 1 | 1 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.780081e-01 | 0.556 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 2.790498e-01 | 0.554 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.808946e-01 | 0.551 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 2.832884e-01 | 0.548 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 2.848704e-01 | 0.545 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 2.848704e-01 | 0.545 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.848704e-01 | 0.545 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.848704e-01 | 0.545 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.925711e-01 | 0.534 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.925711e-01 | 0.534 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.925711e-01 | 0.534 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.001893e-01 | 0.523 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 3.001893e-01 | 0.523 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 3.001893e-01 | 0.523 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.001893e-01 | 0.523 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.018776e-01 | 0.520 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 3.077259e-01 | 0.512 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 3.077259e-01 | 0.512 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 3.151819e-01 | 0.501 | 1 | 1 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.151819e-01 | 0.501 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 3.151819e-01 | 0.501 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 3.216697e-01 | 0.493 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.216697e-01 | 0.493 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 3.216697e-01 | 0.493 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 3.225580e-01 | 0.491 | 1 | 1 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.225580e-01 | 0.491 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.225580e-01 | 0.491 | 1 | 1 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 3.225580e-01 | 0.491 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 3.225580e-01 | 0.491 | 1 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 3.225580e-01 | 0.491 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.298551e-01 | 0.482 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.298551e-01 | 0.482 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.298551e-01 | 0.482 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 3.298551e-01 | 0.482 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.298551e-01 | 0.482 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.298551e-01 | 0.482 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 3.302851e-01 | 0.481 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 3.370740e-01 | 0.472 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.370740e-01 | 0.472 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.370740e-01 | 0.472 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.413234e-01 | 0.467 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 3.413234e-01 | 0.467 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.442157e-01 | 0.463 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.442157e-01 | 0.463 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.442157e-01 | 0.463 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.442157e-01 | 0.463 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.442157e-01 | 0.463 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.442157e-01 | 0.463 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 3.495123e-01 | 0.457 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.512808e-01 | 0.454 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 3.512808e-01 | 0.454 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.512808e-01 | 0.454 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 3.582702e-01 | 0.446 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.582702e-01 | 0.446 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.582702e-01 | 0.446 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.582702e-01 | 0.446 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.582702e-01 | 0.446 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 3.582702e-01 | 0.446 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.651848e-01 | 0.437 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.651848e-01 | 0.437 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.685308e-01 | 0.434 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.720253e-01 | 0.429 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.720253e-01 | 0.429 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.720253e-01 | 0.429 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.720253e-01 | 0.429 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.720253e-01 | 0.429 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.787925e-01 | 0.422 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.787925e-01 | 0.422 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.787925e-01 | 0.422 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 3.787925e-01 | 0.422 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.817033e-01 | 0.418 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.854872e-01 | 0.414 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 3.854872e-01 | 0.414 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.875239e-01 | 0.412 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.921101e-01 | 0.407 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 3.921101e-01 | 0.407 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.921101e-01 | 0.407 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.921101e-01 | 0.407 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.921101e-01 | 0.407 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.921101e-01 | 0.407 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.986621e-01 | 0.399 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.986621e-01 | 0.399 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.986621e-01 | 0.399 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 3.986621e-01 | 0.399 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.048125e-01 | 0.393 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 4.051439e-01 | 0.392 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 4.051439e-01 | 0.392 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.051439e-01 | 0.392 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 4.051439e-01 | 0.392 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 4.051439e-01 | 0.392 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 4.103563e-01 | 0.387 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.115561e-01 | 0.386 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.115561e-01 | 0.386 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.115561e-01 | 0.386 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.115561e-01 | 0.386 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 4.115561e-01 | 0.386 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 4.133912e-01 | 0.384 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 4.178997e-01 | 0.379 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.221438e-01 | 0.375 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.241753e-01 | 0.372 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 4.303836e-01 | 0.366 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 4.303836e-01 | 0.366 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.303836e-01 | 0.366 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.365253e-01 | 0.360 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.365253e-01 | 0.360 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.365253e-01 | 0.360 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.365253e-01 | 0.360 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.365253e-01 | 0.360 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.365253e-01 | 0.360 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.365253e-01 | 0.360 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 4.399176e-01 | 0.357 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.426012e-01 | 0.354 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.426012e-01 | 0.354 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 4.486119e-01 | 0.348 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.486119e-01 | 0.348 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 4.486119e-01 | 0.348 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.543949e-01 | 0.343 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 4.545582e-01 | 0.342 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 4.604408e-01 | 0.337 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.604408e-01 | 0.337 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 4.604408e-01 | 0.337 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.604408e-01 | 0.337 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.604408e-01 | 0.337 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.662602e-01 | 0.331 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 4.699987e-01 | 0.328 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 4.720173e-01 | 0.326 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.720173e-01 | 0.326 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.720173e-01 | 0.326 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.720173e-01 | 0.326 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 4.720173e-01 | 0.326 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.727608e-01 | 0.325 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 4.757060e-01 | 0.323 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 4.777126e-01 | 0.321 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.777126e-01 | 0.321 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.777126e-01 | 0.321 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.777126e-01 | 0.321 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.777126e-01 | 0.321 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.792091e-01 | 0.319 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 4.833468e-01 | 0.316 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 4.833468e-01 | 0.316 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 4.930782e-01 | 0.307 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 4.944346e-01 | 0.306 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.944346e-01 | 0.306 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 4.944346e-01 | 0.306 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.998894e-01 | 0.301 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 4.998894e-01 | 0.301 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 4.998894e-01 | 0.301 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.998894e-01 | 0.301 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.000140e-01 | 0.301 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 5.033269e-01 | 0.298 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 5.052857e-01 | 0.296 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.106242e-01 | 0.292 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 5.106242e-01 | 0.292 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 5.159053e-01 | 0.287 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.211298e-01 | 0.283 | 1 | 1 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.211298e-01 | 0.283 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.211298e-01 | 0.283 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 5.211298e-01 | 0.283 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.211298e-01 | 0.283 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.211298e-01 | 0.283 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.211298e-01 | 0.283 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.211298e-01 | 0.283 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.211298e-01 | 0.283 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 5.234217e-01 | 0.281 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 5.262982e-01 | 0.279 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.262982e-01 | 0.279 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 5.262982e-01 | 0.279 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.262982e-01 | 0.279 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 5.265454e-01 | 0.279 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 5.314112e-01 | 0.275 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.314112e-01 | 0.275 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.314112e-01 | 0.275 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.314112e-01 | 0.275 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 5.314112e-01 | 0.275 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 5.364692e-01 | 0.270 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.364692e-01 | 0.270 | 0 | 0 |
| S Phase | R-HSA-69242 | 5.365140e-01 | 0.270 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 5.414730e-01 | 0.266 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.414730e-01 | 0.266 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 5.414730e-01 | 0.266 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.556879e-01 | 0.255 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 5.561644e-01 | 0.255 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 5.588289e-01 | 0.253 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 5.609568e-01 | 0.251 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.609568e-01 | 0.251 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 5.650636e-01 | 0.248 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 5.662714e-01 | 0.247 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 5.703877e-01 | 0.244 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 5.703877e-01 | 0.244 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.703877e-01 | 0.244 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 5.703877e-01 | 0.244 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.703877e-01 | 0.244 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.703877e-01 | 0.244 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 5.750274e-01 | 0.240 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.750274e-01 | 0.240 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 5.796172e-01 | 0.237 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 5.796172e-01 | 0.237 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.886495e-01 | 0.230 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.886495e-01 | 0.230 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.886495e-01 | 0.230 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.974889e-01 | 0.224 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.974889e-01 | 0.224 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.018375e-01 | 0.221 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.035853e-01 | 0.219 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.061394e-01 | 0.217 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 6.061394e-01 | 0.217 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 6.061394e-01 | 0.217 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 6.103950e-01 | 0.214 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.103950e-01 | 0.214 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 6.110947e-01 | 0.214 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 6.146050e-01 | 0.211 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 6.187697e-01 | 0.208 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.187697e-01 | 0.208 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 6.211328e-01 | 0.207 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.269653e-01 | 0.203 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.269653e-01 | 0.203 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.309972e-01 | 0.200 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.349858e-01 | 0.197 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.349858e-01 | 0.197 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 6.355752e-01 | 0.197 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 6.375471e-01 | 0.195 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.389315e-01 | 0.195 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.542947e-01 | 0.184 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 6.580328e-01 | 0.182 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.580328e-01 | 0.182 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.690078e-01 | 0.175 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 6.725877e-01 | 0.172 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.830981e-01 | 0.166 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.865265e-01 | 0.163 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 6.932730e-01 | 0.159 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.932730e-01 | 0.159 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.932730e-01 | 0.159 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.932730e-01 | 0.159 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 6.932730e-01 | 0.159 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 6.934131e-01 | 0.159 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.998752e-01 | 0.155 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.998752e-01 | 0.155 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 7.027609e-01 | 0.153 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.063360e-01 | 0.151 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.126585e-01 | 0.147 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 7.163400e-01 | 0.145 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 7.188457e-01 | 0.143 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.218894e-01 | 0.142 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.218894e-01 | 0.142 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 7.278790e-01 | 0.138 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.278790e-01 | 0.138 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.278790e-01 | 0.138 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.293977e-01 | 0.137 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 7.308254e-01 | 0.136 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.308254e-01 | 0.136 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.337402e-01 | 0.134 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.337402e-01 | 0.134 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.385997e-01 | 0.132 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.422975e-01 | 0.129 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.478500e-01 | 0.126 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.505814e-01 | 0.125 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.532834e-01 | 0.123 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.586004e-01 | 0.120 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 7.638035e-01 | 0.117 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 7.638035e-01 | 0.117 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 7.688951e-01 | 0.114 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.713998e-01 | 0.113 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.713998e-01 | 0.113 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 7.811516e-01 | 0.107 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 7.835242e-01 | 0.106 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.972323e-01 | 0.098 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.994315e-01 | 0.097 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 8.121377e-01 | 0.090 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.141761e-01 | 0.089 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 8.141761e-01 | 0.089 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 8.201605e-01 | 0.086 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 8.233317e-01 | 0.084 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.240432e-01 | 0.084 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 8.259532e-01 | 0.083 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 8.259532e-01 | 0.083 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 8.315604e-01 | 0.080 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 8.319596e-01 | 0.080 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 8.333892e-01 | 0.079 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 8.351983e-01 | 0.078 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.387581e-01 | 0.076 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.405093e-01 | 0.075 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 8.422415e-01 | 0.075 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.422415e-01 | 0.075 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.439550e-01 | 0.074 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 8.489853e-01 | 0.071 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.506260e-01 | 0.070 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 8.524907e-01 | 0.069 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.538544e-01 | 0.069 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.616250e-01 | 0.065 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 8.660887e-01 | 0.062 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.718184e-01 | 0.060 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 8.759551e-01 | 0.058 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 8.759551e-01 | 0.058 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 8.825567e-01 | 0.054 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 8.838345e-01 | 0.054 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 8.870058e-01 | 0.052 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 8.881029e-01 | 0.052 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 8.900190e-01 | 0.051 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 8.924001e-01 | 0.049 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.958760e-01 | 0.048 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 8.981311e-01 | 0.047 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 9.003375e-01 | 0.046 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 9.048329e-01 | 0.043 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.086982e-01 | 0.042 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 9.199494e-01 | 0.036 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.274729e-01 | 0.033 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.384814e-01 | 0.028 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.454828e-01 | 0.024 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.470245e-01 | 0.024 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.470245e-01 | 0.024 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.547760e-01 | 0.020 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.547856e-01 | 0.020 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.612331e-01 | 0.017 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.628494e-01 | 0.016 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.678533e-01 | 0.014 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.743968e-01 | 0.011 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 9.756004e-01 | 0.011 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.766545e-01 | 0.010 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.806517e-01 | 0.008 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.868654e-01 | 0.006 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.893591e-01 | 0.005 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.926235e-01 | 0.003 | 0 | 0 |
| Translation | R-HSA-72766 | 9.927856e-01 | 0.003 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.974705e-01 | 0.001 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.976758e-01 | 0.001 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.987927e-01 | 0.001 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.991286e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999888e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.000000e+00 | 0.000 | 1 | 1 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.000000e+00 | 0.000 | 1 | 1 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.000000e+00 | 0.000 | 1 | 1 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.000000e+00 | 0.000 | 1 | 1 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.000000e+00 | 0.000 | 1 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.000000e+00 | 0.000 | 1 | 1 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.000000e+00 | 0.000 | 1 | 1 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.000000e+00 | 0.000 | 1 | 1 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Attenuation phase | R-HSA-3371568 | 1.110223e-16 | 15.955 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.110223e-16 | 15.955 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.110223e-16 | 15.955 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 2.220557e-12 | 11.654 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.525080e-11 | 10.817 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.576220e-06 | 5.802 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.478994e-06 | 5.830 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.965745e-06 | 5.706 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.733362e-06 | 5.563 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 3.021894e-06 | 5.520 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.000223e-06 | 5.398 | 1 | 1 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.691940e-06 | 5.329 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 7.429201e-06 | 5.129 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 9.518511e-06 | 5.021 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.688712e-05 | 4.772 | 1 | 1 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.627953e-05 | 4.788 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 3.405366e-05 | 4.468 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.073164e-05 | 4.390 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.470716e-05 | 4.262 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.013904e-05 | 4.154 | 1 | 1 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 7.884142e-05 | 4.103 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.884142e-05 | 4.103 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 7.884142e-05 | 4.103 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.464935e-05 | 4.072 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 9.129967e-05 | 4.040 | 1 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.007258e-04 | 3.997 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.155622e-04 | 3.937 | 1 | 1 |
| Axon guidance | R-HSA-422475 | 1.136472e-04 | 3.944 | 1 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.135055e-04 | 3.945 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.633256e-04 | 3.787 | 1 | 1 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.633256e-04 | 3.787 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.681058e-04 | 3.774 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 2.321195e-04 | 3.634 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.453991e-04 | 3.610 | 1 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.864166e-04 | 3.543 | 1 | 1 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.430118e-04 | 3.465 | 1 | 1 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 3.483376e-04 | 3.458 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.721092e-04 | 3.429 | 1 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.844451e-04 | 3.415 | 1 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 4.440023e-04 | 3.353 | 1 | 1 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.388364e-04 | 3.358 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 4.284638e-04 | 3.368 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 5.836765e-04 | 3.234 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 5.988435e-04 | 3.223 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 6.157192e-04 | 3.211 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.029798e-03 | 2.987 | 1 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.029798e-03 | 2.987 | 1 | 1 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.029798e-03 | 2.987 | 1 | 1 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.029798e-03 | 2.987 | 1 | 1 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 9.036784e-04 | 3.044 | 1 | 1 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.036784e-04 | 3.044 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.866009e-04 | 3.104 | 1 | 1 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 8.725952e-04 | 3.059 | 1 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 8.352699e-04 | 3.078 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 9.610629e-04 | 3.017 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 8.725952e-04 | 3.059 | 1 | 1 |
| Smooth Muscle Contraction | R-HSA-445355 | 7.771902e-04 | 3.109 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.064100e-03 | 2.973 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.100422e-03 | 2.958 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.190593e-03 | 2.924 | 1 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.283332e-03 | 2.892 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.513975e-03 | 2.820 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.513975e-03 | 2.820 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.443905e-03 | 2.840 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.475410e-03 | 2.831 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.403984e-03 | 2.853 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.513975e-03 | 2.820 | 1 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.532587e-03 | 2.815 | 1 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.739908e-03 | 2.759 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.811301e-03 | 2.742 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.959552e-03 | 2.708 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.118213e-03 | 2.674 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.233244e-03 | 2.651 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.233244e-03 | 2.651 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 2.282170e-03 | 2.642 | 1 | 1 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.478133e-03 | 2.606 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.668737e-03 | 2.574 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.651854e-03 | 2.576 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.856448e-03 | 2.544 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.866283e-03 | 2.543 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.907770e-03 | 2.536 | 1 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.960020e-03 | 2.529 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.028224e-03 | 2.519 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 3.028224e-03 | 2.519 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.564275e-03 | 2.448 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.564275e-03 | 2.448 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.195379e-03 | 2.495 | 1 | 1 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.195379e-03 | 2.495 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.294106e-03 | 2.482 | 1 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.636648e-03 | 2.439 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 3.763486e-03 | 2.424 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.763486e-03 | 2.424 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 3.996235e-03 | 2.398 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 4.033688e-03 | 2.394 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 4.127673e-03 | 2.384 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 4.276261e-03 | 2.369 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.560401e-03 | 2.341 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 4.575260e-03 | 2.340 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.822850e-03 | 2.317 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 5.676097e-03 | 2.246 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 5.676097e-03 | 2.246 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 5.793098e-03 | 2.237 | 1 | 0 |
| Muscle contraction | R-HSA-397014 | 5.927665e-03 | 2.227 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.092627e-03 | 2.215 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 6.150478e-03 | 2.211 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.171998e-03 | 2.210 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 6.221631e-03 | 2.206 | 1 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.318832e-03 | 2.199 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.971835e-03 | 2.157 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 7.386143e-03 | 2.132 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 8.724114e-03 | 2.059 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 8.724114e-03 | 2.059 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 8.724114e-03 | 2.059 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 8.700806e-03 | 2.060 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 8.248886e-03 | 2.084 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 8.434848e-03 | 2.074 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.224603e-03 | 2.035 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 9.454027e-03 | 2.024 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.481589e-03 | 2.023 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.148454e-02 | 1.940 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.148454e-02 | 1.940 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.148454e-02 | 1.940 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.148454e-02 | 1.940 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.148454e-02 | 1.940 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.148454e-02 | 1.940 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.016191e-02 | 1.993 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.016191e-02 | 1.993 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.078863e-02 | 1.967 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.016191e-02 | 1.993 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 1.014448e-02 | 1.994 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.062591e-02 | 1.974 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.062591e-02 | 1.974 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.078863e-02 | 1.967 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 1.016191e-02 | 1.993 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 9.677438e-03 | 2.014 | 1 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 9.677438e-03 | 2.014 | 1 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.072275e-02 | 1.970 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.016191e-02 | 1.993 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.015855e-02 | 1.993 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 1.154331e-02 | 1.938 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.157605e-02 | 1.936 | 1 | 1 |
| PECAM1 interactions | R-HSA-210990 | 1.169707e-02 | 1.932 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.169707e-02 | 1.932 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.169707e-02 | 1.932 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.169707e-02 | 1.932 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.232769e-02 | 1.909 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.256193e-02 | 1.901 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.293289e-02 | 1.888 | 1 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.309430e-02 | 1.883 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.332721e-02 | 1.875 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.332721e-02 | 1.875 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.333667e-02 | 1.875 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.333667e-02 | 1.875 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.504997e-02 | 1.822 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.504997e-02 | 1.822 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.398626e-02 | 1.854 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.501295e-02 | 1.824 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.632937e-02 | 1.787 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.486074e-02 | 1.828 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.441116e-02 | 1.841 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.501295e-02 | 1.824 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.410273e-02 | 1.851 | 1 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.427964e-02 | 1.845 | 1 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 1.670069e-02 | 1.777 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.702126e-02 | 1.769 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.764533e-02 | 1.753 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.766636e-02 | 1.753 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.783710e-02 | 1.749 | 1 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.817457e-02 | 1.741 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.817457e-02 | 1.741 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.817457e-02 | 1.741 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.825901e-02 | 1.739 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.876409e-02 | 1.727 | 1 | 1 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.876409e-02 | 1.727 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.876409e-02 | 1.727 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.926427e-02 | 1.715 | 1 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.074694e-02 | 1.683 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.075094e-02 | 1.683 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.075094e-02 | 1.683 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.075094e-02 | 1.683 | 1 | 1 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 2.075094e-02 | 1.683 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.282137e-02 | 1.642 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.283790e-02 | 1.641 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.283790e-02 | 1.641 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.497322e-02 | 1.603 | 1 | 1 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.720437e-02 | 1.565 | 1 | 1 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.720437e-02 | 1.565 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.900825e-02 | 1.537 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.953756e-02 | 1.530 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 3.047043e-02 | 1.516 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.495442e-02 | 1.603 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.495442e-02 | 1.603 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 2.497322e-02 | 1.603 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 2.410357e-02 | 1.618 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.951273e-02 | 1.530 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.574499e-02 | 1.589 | 1 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.684204e-02 | 1.571 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.739832e-02 | 1.562 | 1 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.404997e-02 | 1.619 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 2.773620e-02 | 1.557 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.404997e-02 | 1.619 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.720437e-02 | 1.565 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.951273e-02 | 1.530 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 2.497322e-02 | 1.603 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.862190e-02 | 1.543 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.951273e-02 | 1.530 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 2.839820e-02 | 1.547 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.238799e-02 | 1.490 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.300699e-02 | 1.481 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 3.300699e-02 | 1.481 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.337275e-02 | 1.477 | 1 | 1 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.406154e-02 | 1.468 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.406154e-02 | 1.468 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.406154e-02 | 1.468 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.406154e-02 | 1.468 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.406154e-02 | 1.468 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 3.414320e-02 | 1.467 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.435296e-02 | 1.464 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 3.437485e-02 | 1.464 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 3.437485e-02 | 1.464 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 3.440048e-02 | 1.463 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 3.495073e-02 | 1.457 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.539434e-02 | 1.451 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 3.539434e-02 | 1.451 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.577001e-02 | 1.446 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 3.688083e-02 | 1.433 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 3.688083e-02 | 1.433 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 3.744399e-02 | 1.427 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 3.947794e-02 | 1.404 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.947794e-02 | 1.404 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.947794e-02 | 1.404 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.013337e-02 | 1.396 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.027432e-02 | 1.395 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.075310e-02 | 1.390 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.096723e-02 | 1.388 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.187718e-02 | 1.378 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 4.515696e-02 | 1.345 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 4.766584e-02 | 1.322 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 4.766584e-02 | 1.322 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.641036e-02 | 1.249 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.641036e-02 | 1.249 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 5.641036e-02 | 1.249 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.252596e-02 | 1.204 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 6.252596e-02 | 1.204 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 6.252596e-02 | 1.204 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 4.417769e-02 | 1.355 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 5.023385e-02 | 1.299 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.566451e-02 | 1.183 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 5.672344e-02 | 1.246 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 5.672344e-02 | 1.246 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 5.641036e-02 | 1.249 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 4.828071e-02 | 1.316 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.448318e-02 | 1.191 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.448318e-02 | 1.191 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 6.566451e-02 | 1.183 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 4.487230e-02 | 1.348 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 5.277787e-02 | 1.278 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 5.612561e-02 | 1.251 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 6.257285e-02 | 1.204 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 4.515696e-02 | 1.345 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 4.515696e-02 | 1.345 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.535410e-02 | 1.343 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 5.407582e-02 | 1.267 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 6.252596e-02 | 1.204 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.943973e-02 | 1.226 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.023385e-02 | 1.299 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 4.535410e-02 | 1.343 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.152262e-02 | 1.288 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 4.781909e-02 | 1.320 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 6.252596e-02 | 1.204 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 6.566451e-02 | 1.183 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 4.461608e-02 | 1.351 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 4.849022e-02 | 1.314 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 4.652903e-02 | 1.332 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 5.641036e-02 | 1.249 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 5.641036e-02 | 1.249 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.023385e-02 | 1.299 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 4.487230e-02 | 1.348 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.023385e-02 | 1.299 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 4.383787e-02 | 1.358 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 5.137891e-02 | 1.289 | 1 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 5.641036e-02 | 1.249 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.652839e-02 | 1.177 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 6.696892e-02 | 1.174 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 6.696892e-02 | 1.174 | 1 | 1 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 6.696892e-02 | 1.174 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 6.696892e-02 | 1.174 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 6.696892e-02 | 1.174 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 6.885473e-02 | 1.162 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 7.209503e-02 | 1.142 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 7.209503e-02 | 1.142 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 7.209503e-02 | 1.142 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 7.538385e-02 | 1.123 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.538385e-02 | 1.123 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.538385e-02 | 1.123 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 7.538385e-02 | 1.123 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.538385e-02 | 1.123 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 7.558820e-02 | 1.122 | 1 | 1 |
| Disease | R-HSA-1643685 | 7.677215e-02 | 1.115 | 1 | 0 |
| IRS activation | R-HSA-74713 | 7.768833e-02 | 1.110 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 7.768833e-02 | 1.110 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 7.768833e-02 | 1.110 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 7.768833e-02 | 1.110 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 7.858969e-02 | 1.105 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 7.916170e-02 | 1.101 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.210099e-02 | 1.086 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.210099e-02 | 1.086 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.828524e-02 | 1.054 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 8.828524e-02 | 1.054 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 8.828524e-02 | 1.054 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 9.876105e-02 | 1.005 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 9.876105e-02 | 1.005 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 9.876105e-02 | 1.005 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 9.876105e-02 | 1.005 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.091171e-01 | 0.962 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.091171e-01 | 0.962 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.091171e-01 | 0.962 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 1.091171e-01 | 0.962 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.091171e-01 | 0.962 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.091171e-01 | 0.962 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.193548e-01 | 0.923 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 1.193548e-01 | 0.923 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.193548e-01 | 0.923 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.193548e-01 | 0.923 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.294755e-01 | 0.888 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 1.294755e-01 | 0.888 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.394805e-01 | 0.855 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 1.493711e-01 | 0.826 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.591486e-01 | 0.798 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 1.591486e-01 | 0.798 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.591486e-01 | 0.798 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 8.552634e-02 | 1.068 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.295651e-01 | 0.888 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.295651e-01 | 0.888 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 1.531894e-01 | 0.815 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.572058e-01 | 0.804 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.022390e-01 | 0.990 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.106185e-01 | 0.956 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.295651e-01 | 0.888 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.295651e-01 | 0.888 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.394805e-01 | 0.855 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.295651e-01 | 0.888 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.605223e-02 | 1.017 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.032639e-01 | 0.986 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.193975e-01 | 0.923 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 1.091171e-01 | 0.962 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.193548e-01 | 0.923 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 1.591486e-01 | 0.798 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 9.250336e-02 | 1.034 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.106185e-01 | 0.956 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.572058e-01 | 0.804 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 1.295651e-01 | 0.888 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 8.828524e-02 | 1.054 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 1.118093e-01 | 0.952 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.572058e-01 | 0.804 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 1.193548e-01 | 0.923 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 1.394805e-01 | 0.855 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.394805e-01 | 0.855 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 1.493711e-01 | 0.826 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.069240e-01 | 0.971 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 1.491939e-01 | 0.826 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.531894e-01 | 0.815 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.572058e-01 | 0.804 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 1.572058e-01 | 0.804 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.612419e-01 | 0.793 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.552634e-02 | 1.068 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.069240e-01 | 0.971 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 1.091171e-01 | 0.962 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 1.257167e-01 | 0.901 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.552634e-02 | 1.068 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 1.193548e-01 | 0.923 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.394805e-01 | 0.855 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.591486e-01 | 0.798 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 9.605223e-02 | 1.017 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 8.899427e-02 | 1.051 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 1.193548e-01 | 0.923 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.294755e-01 | 0.888 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.294755e-01 | 0.888 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 1.591486e-01 | 0.798 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.374433e-01 | 0.862 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.642025e-01 | 0.785 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 1.257167e-01 | 0.901 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.552634e-02 | 1.068 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 1.293158e-01 | 0.888 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 9.876105e-02 | 1.005 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.294755e-01 | 0.888 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.294755e-01 | 0.888 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.394805e-01 | 0.855 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 1.591486e-01 | 0.798 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.143463e-01 | 0.942 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.295651e-01 | 0.888 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.828524e-02 | 1.054 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 8.828524e-02 | 1.054 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 9.876105e-02 | 1.005 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 1.091171e-01 | 0.962 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.007445e-01 | 0.997 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.257167e-01 | 0.901 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.257167e-01 | 0.901 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.273164e-01 | 0.895 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.032639e-01 | 0.986 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.552634e-02 | 1.068 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.005759e-01 | 0.998 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.552634e-02 | 1.068 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.008371e-01 | 0.996 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 9.632816e-02 | 1.016 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 1.478849e-01 | 0.830 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.114366e-01 | 0.953 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.091171e-01 | 0.962 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 9.850467e-02 | 1.007 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 1.491939e-01 | 0.826 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.181061e-01 | 0.928 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.257167e-01 | 0.901 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.013265e-02 | 1.045 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.899427e-02 | 1.051 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 1.181061e-01 | 0.928 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 9.963951e-02 | 1.002 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.608061e-01 | 0.794 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.605223e-02 | 1.017 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.161814e-01 | 0.935 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 1.493711e-01 | 0.826 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 9.963951e-02 | 1.002 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 1.435247e-01 | 0.843 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.521459e-01 | 0.818 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 1.353922e-01 | 0.868 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.652969e-01 | 0.782 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.688144e-01 | 0.773 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.688144e-01 | 0.773 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.688144e-01 | 0.773 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.688144e-01 | 0.773 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.688144e-01 | 0.773 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.688144e-01 | 0.773 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.688144e-01 | 0.773 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.688144e-01 | 0.773 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.688144e-01 | 0.773 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.688144e-01 | 0.773 | 1 | 1 |
| Signaling by EGFR | R-HSA-177929 | 1.693698e-01 | 0.771 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 1.693698e-01 | 0.771 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.693698e-01 | 0.771 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.693698e-01 | 0.771 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.775655e-01 | 0.751 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.780860e-01 | 0.749 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.783696e-01 | 0.749 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.783696e-01 | 0.749 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.783696e-01 | 0.749 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 1.783696e-01 | 0.749 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.783696e-01 | 0.749 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.855054e-01 | 0.732 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.858218e-01 | 0.731 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.858218e-01 | 0.731 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 1.878156e-01 | 0.726 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 1.878156e-01 | 0.726 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.885443e-01 | 0.725 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 1.899704e-01 | 0.721 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.941316e-01 | 0.712 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.941316e-01 | 0.712 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.971535e-01 | 0.705 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.971535e-01 | 0.705 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.971535e-01 | 0.705 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 1.971535e-01 | 0.705 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.971535e-01 | 0.705 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.971535e-01 | 0.705 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.971535e-01 | 0.705 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 1.971535e-01 | 0.705 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.983045e-01 | 0.703 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.996251e-01 | 0.700 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.024883e-01 | 0.694 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 2.024883e-01 | 0.694 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.063847e-01 | 0.685 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.063847e-01 | 0.685 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 2.063847e-01 | 0.685 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 2.063847e-01 | 0.685 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.063847e-01 | 0.685 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.065724e-01 | 0.685 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.066822e-01 | 0.685 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.066822e-01 | 0.685 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.139359e-01 | 0.670 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 2.150971e-01 | 0.667 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.155103e-01 | 0.667 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 2.155103e-01 | 0.667 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 2.155103e-01 | 0.667 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.155103e-01 | 0.667 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 2.155103e-01 | 0.667 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.155103e-01 | 0.667 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.159930e-01 | 0.666 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 2.193167e-01 | 0.659 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.235434e-01 | 0.651 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.245315e-01 | 0.649 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 2.245315e-01 | 0.649 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.277764e-01 | 0.642 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.277764e-01 | 0.642 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.282957e-01 | 0.642 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.296861e-01 | 0.639 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.334495e-01 | 0.632 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.334495e-01 | 0.632 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.334495e-01 | 0.632 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 2.334495e-01 | 0.632 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.362588e-01 | 0.627 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.362588e-01 | 0.627 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 2.422655e-01 | 0.616 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.422655e-01 | 0.616 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.422655e-01 | 0.616 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.422655e-01 | 0.616 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 2.422655e-01 | 0.616 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.422655e-01 | 0.616 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.422655e-01 | 0.616 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.422655e-01 | 0.616 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.422655e-01 | 0.616 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.422655e-01 | 0.616 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.422655e-01 | 0.616 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.422655e-01 | 0.616 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.447585e-01 | 0.611 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.447585e-01 | 0.611 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.449277e-01 | 0.611 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 2.490132e-01 | 0.604 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.509806e-01 | 0.600 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.509806e-01 | 0.600 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.509806e-01 | 0.600 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.509806e-01 | 0.600 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.509806e-01 | 0.600 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.509806e-01 | 0.600 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.532703e-01 | 0.596 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.595961e-01 | 0.586 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.603261e-01 | 0.584 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.617892e-01 | 0.582 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.617892e-01 | 0.582 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.648613e-01 | 0.577 | 0 | 0 |
| Translation | R-HSA-72766 | 2.655272e-01 | 0.576 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.681130e-01 | 0.572 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.681130e-01 | 0.572 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.681130e-01 | 0.572 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.681130e-01 | 0.572 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.681130e-01 | 0.572 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.681130e-01 | 0.572 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.703106e-01 | 0.568 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.703106e-01 | 0.568 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.703106e-01 | 0.568 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.745707e-01 | 0.561 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 2.765324e-01 | 0.558 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.765324e-01 | 0.558 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.765324e-01 | 0.558 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 2.765324e-01 | 0.558 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.788298e-01 | 0.555 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.820846e-01 | 0.550 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.829371e-01 | 0.548 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 2.830872e-01 | 0.548 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 2.848555e-01 | 0.545 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.848555e-01 | 0.545 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.848555e-01 | 0.545 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.848555e-01 | 0.545 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.852077e-01 | 0.545 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.915952e-01 | 0.535 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.915952e-01 | 0.535 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.915952e-01 | 0.535 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 2.958448e-01 | 0.529 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 2.977271e-01 | 0.526 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 3.000906e-01 | 0.523 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 3.012170e-01 | 0.521 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.012170e-01 | 0.521 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 3.012170e-01 | 0.521 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 3.012170e-01 | 0.521 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.012170e-01 | 0.521 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 3.043324e-01 | 0.517 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.043324e-01 | 0.517 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.092576e-01 | 0.510 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.092576e-01 | 0.510 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 3.092576e-01 | 0.510 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.092576e-01 | 0.510 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 3.092576e-01 | 0.510 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.092576e-01 | 0.510 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.172062e-01 | 0.499 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.172062e-01 | 0.499 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.172062e-01 | 0.499 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 3.172062e-01 | 0.499 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.197046e-01 | 0.495 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.212494e-01 | 0.493 | 0 | 0 |
| M Phase | R-HSA-68886 | 3.229626e-01 | 0.491 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 3.248145e-01 | 0.488 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.250637e-01 | 0.488 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.250637e-01 | 0.488 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 3.250637e-01 | 0.488 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.250637e-01 | 0.488 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 3.250637e-01 | 0.488 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 3.250637e-01 | 0.488 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 3.254639e-01 | 0.487 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.296717e-01 | 0.482 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.296717e-01 | 0.482 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 3.328314e-01 | 0.478 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 3.405101e-01 | 0.468 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.405101e-01 | 0.468 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 3.405101e-01 | 0.468 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 3.405101e-01 | 0.468 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.481009e-01 | 0.458 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.481009e-01 | 0.458 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 3.481009e-01 | 0.458 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.481009e-01 | 0.458 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.481009e-01 | 0.458 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.505960e-01 | 0.455 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.547554e-01 | 0.450 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.556048e-01 | 0.449 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.556048e-01 | 0.449 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.567872e-01 | 0.448 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.589055e-01 | 0.445 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 3.630228e-01 | 0.440 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.630228e-01 | 0.440 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.630228e-01 | 0.440 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 3.630228e-01 | 0.440 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.703559e-01 | 0.431 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.703559e-01 | 0.431 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 3.754058e-01 | 0.425 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 3.761517e-01 | 0.425 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.776050e-01 | 0.423 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 3.776050e-01 | 0.423 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 3.776050e-01 | 0.423 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.776050e-01 | 0.423 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.776050e-01 | 0.423 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.776050e-01 | 0.423 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 3.776050e-01 | 0.423 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 3.776050e-01 | 0.423 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 3.792687e-01 | 0.421 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 3.818751e-01 | 0.418 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.823824e-01 | 0.418 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.847710e-01 | 0.415 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.847710e-01 | 0.415 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.847710e-01 | 0.415 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 3.847710e-01 | 0.415 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.917319e-01 | 0.407 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.918550e-01 | 0.407 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.918550e-01 | 0.407 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.918550e-01 | 0.407 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 3.978971e-01 | 0.400 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.988579e-01 | 0.399 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 3.988579e-01 | 0.399 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.988579e-01 | 0.399 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.988579e-01 | 0.399 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.988579e-01 | 0.399 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 4.057805e-01 | 0.392 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 4.057805e-01 | 0.392 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.057805e-01 | 0.392 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.118672e-01 | 0.385 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.118672e-01 | 0.385 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.126239e-01 | 0.384 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 4.126239e-01 | 0.384 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 4.126239e-01 | 0.384 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 4.126239e-01 | 0.384 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 4.126239e-01 | 0.384 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.126239e-01 | 0.384 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.193888e-01 | 0.377 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.193888e-01 | 0.377 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.193888e-01 | 0.377 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.193888e-01 | 0.377 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.193888e-01 | 0.377 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 4.193888e-01 | 0.377 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.198302e-01 | 0.377 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 4.260763e-01 | 0.371 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.260763e-01 | 0.371 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 4.260763e-01 | 0.371 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 4.260763e-01 | 0.371 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 4.261742e-01 | 0.370 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 4.277385e-01 | 0.369 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 4.316353e-01 | 0.365 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.326871e-01 | 0.364 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.326871e-01 | 0.364 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.326871e-01 | 0.364 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.326871e-01 | 0.364 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.326871e-01 | 0.364 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.326871e-01 | 0.364 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 4.392222e-01 | 0.357 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 4.392222e-01 | 0.357 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 4.392222e-01 | 0.357 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.415397e-01 | 0.355 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.456825e-01 | 0.351 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 4.456825e-01 | 0.351 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 4.456825e-01 | 0.351 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 4.511187e-01 | 0.346 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 4.520687e-01 | 0.345 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 4.520687e-01 | 0.345 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 4.520687e-01 | 0.345 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 4.520687e-01 | 0.345 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.520687e-01 | 0.345 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 4.549633e-01 | 0.342 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.583817e-01 | 0.339 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.583817e-01 | 0.339 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.583817e-01 | 0.339 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 4.626061e-01 | 0.335 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 4.646223e-01 | 0.333 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.646223e-01 | 0.333 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.646223e-01 | 0.333 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.646223e-01 | 0.333 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.646223e-01 | 0.333 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 4.705987e-01 | 0.327 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 4.707915e-01 | 0.327 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.707915e-01 | 0.327 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.707915e-01 | 0.327 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 4.720350e-01 | 0.326 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.739525e-01 | 0.324 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 4.768899e-01 | 0.322 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 4.829184e-01 | 0.316 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.829184e-01 | 0.316 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.829184e-01 | 0.316 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.888554e-01 | 0.311 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.888779e-01 | 0.311 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 4.888779e-01 | 0.311 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.947690e-01 | 0.306 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.947690e-01 | 0.306 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.947690e-01 | 0.306 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 5.005925e-01 | 0.301 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.005925e-01 | 0.301 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 5.005925e-01 | 0.301 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 5.005925e-01 | 0.301 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.005925e-01 | 0.301 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.034933e-01 | 0.298 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 5.071106e-01 | 0.295 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 5.107108e-01 | 0.292 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.120401e-01 | 0.291 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 5.142939e-01 | 0.289 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.176656e-01 | 0.286 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.232267e-01 | 0.281 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 5.232267e-01 | 0.281 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.284531e-01 | 0.277 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 5.287239e-01 | 0.277 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 5.287239e-01 | 0.277 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 5.287239e-01 | 0.277 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 5.388887e-01 | 0.269 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 5.395300e-01 | 0.268 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.395300e-01 | 0.268 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 5.395300e-01 | 0.268 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 5.423320e-01 | 0.266 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 5.423320e-01 | 0.266 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 5.423320e-01 | 0.266 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.446336e-01 | 0.264 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.448402e-01 | 0.264 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.500896e-01 | 0.260 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 5.500896e-01 | 0.260 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 5.500896e-01 | 0.260 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 5.500896e-01 | 0.260 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.654790e-01 | 0.248 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 5.725169e-01 | 0.242 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.754466e-01 | 0.240 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 5.803448e-01 | 0.236 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 5.803448e-01 | 0.236 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 5.822543e-01 | 0.235 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.851868e-01 | 0.233 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 5.854639e-01 | 0.232 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 5.871897e-01 | 0.231 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 5.886554e-01 | 0.230 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.947047e-01 | 0.226 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 5.947047e-01 | 0.226 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.947047e-01 | 0.226 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 5.993818e-01 | 0.222 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 5.993818e-01 | 0.222 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.993818e-01 | 0.222 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 6.014563e-01 | 0.221 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.085757e-01 | 0.216 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.085757e-01 | 0.216 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 6.085757e-01 | 0.216 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 6.085757e-01 | 0.216 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 6.130936e-01 | 0.212 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 6.175597e-01 | 0.209 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.175597e-01 | 0.209 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.219744e-01 | 0.206 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 6.306525e-01 | 0.200 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.391324e-01 | 0.194 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.474186e-01 | 0.189 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.514905e-01 | 0.186 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 6.555156e-01 | 0.183 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.570629e-01 | 0.182 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.594944e-01 | 0.181 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 6.673155e-01 | 0.176 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 6.706802e-01 | 0.173 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 6.711588e-01 | 0.173 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.749579e-01 | 0.171 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 6.774321e-01 | 0.169 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 6.774321e-01 | 0.169 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.787133e-01 | 0.168 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 6.824256e-01 | 0.166 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.824256e-01 | 0.166 | 0 | 0 |
| Protein folding | R-HSA-391251 | 6.933085e-01 | 0.159 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 6.968530e-01 | 0.157 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 6.991040e-01 | 0.155 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 7.003568e-01 | 0.155 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 7.068184e-01 | 0.151 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.072440e-01 | 0.150 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 7.106283e-01 | 0.148 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 7.106283e-01 | 0.148 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.106283e-01 | 0.148 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 7.139737e-01 | 0.146 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 7.205495e-01 | 0.142 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 7.208301e-01 | 0.142 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 7.237808e-01 | 0.140 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 7.237808e-01 | 0.140 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 7.269750e-01 | 0.138 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 7.277744e-01 | 0.138 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 7.301324e-01 | 0.137 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.363386e-01 | 0.133 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 7.393883e-01 | 0.131 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.453828e-01 | 0.128 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 7.483285e-01 | 0.126 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 7.498781e-01 | 0.125 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.512402e-01 | 0.124 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 7.512402e-01 | 0.124 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 7.549530e-01 | 0.122 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 7.582809e-01 | 0.120 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.594049e-01 | 0.120 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 7.603434e-01 | 0.119 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 7.625558e-01 | 0.118 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 7.684423e-01 | 0.114 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 7.759830e-01 | 0.110 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.759830e-01 | 0.110 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 7.782321e-01 | 0.109 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.811399e-01 | 0.107 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 7.811399e-01 | 0.107 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 7.886547e-01 | 0.103 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 7.911022e-01 | 0.102 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 7.911022e-01 | 0.102 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 7.939397e-01 | 0.100 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 7.959128e-01 | 0.099 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.959128e-01 | 0.099 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 8.037476e-01 | 0.095 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 8.052060e-01 | 0.094 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 8.169736e-01 | 0.088 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 8.183624e-01 | 0.087 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 8.188463e-01 | 0.087 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 8.204676e-01 | 0.086 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 8.345393e-01 | 0.079 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.439136e-01 | 0.074 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.475136e-01 | 0.072 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.578257e-01 | 0.067 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 8.642363e-01 | 0.063 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 8.653668e-01 | 0.063 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.689828e-01 | 0.061 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.705039e-01 | 0.060 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 8.734936e-01 | 0.059 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.792686e-01 | 0.056 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.900437e-01 | 0.051 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 8.925845e-01 | 0.049 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 8.925845e-01 | 0.049 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.008015e-01 | 0.045 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.149910e-01 | 0.039 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.179245e-01 | 0.037 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.430275e-01 | 0.025 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.487202e-01 | 0.023 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.553935e-01 | 0.020 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.569380e-01 | 0.019 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.577426e-01 | 0.019 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.634712e-01 | 0.016 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.652116e-01 | 0.015 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.690177e-01 | 0.014 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.887702e-01 | 0.005 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.947422e-01 | 0.002 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.974320e-01 | 0.001 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.983253e-01 | 0.001 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.999967e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999977e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999997e-01 | 0.000 | 0 | 0 |